No Cure for Something Indicates We Are Still Too Young
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
The persistence of diseases for which no cure exists underscores both the limitations of current medical science and the broader developmental stage of humanity’s understanding of biology. Conditions such as Alzheimer’s disease, certain cancers, autoimmune disorders, and rare genetic syndromes remind us that despite technological advancements, we remain in the infancy of comprehending complex biological systems. The absence of cures is not merely a scientific challenge but also a philosophical reflection on human maturity, patience, and humility. This article argues that recognizing our current limitations should inspire renewed investment in basic science, interdisciplinary research, and ethical innovation rather than despair. By acknowledging that the lack of cures signals both our scientific youth and the complexity of life, society can adopt a more measured and aspirational approach to medical progress. In doing so, we not only improve the prospects for future cures but also cultivate a more informed, resilient, and thoughtful scientific culture.
##plugins.themes.bootstrap3.article.details##
Medical Progress, Incurable Diseases, Human Development, Scientific Maturity, Biomedical Research
No funding source declared.
Ariga, H. (2015). Common mecha-nisms of onset of cancer and neurodegenerative diseases. Bio-logical & Pharmaceutical Bulletin, 38(6), 795–808. DOI: https://doi.org/10.1248/bpb.b15-00125
Fischer, D. S., Villanueva, M. A., Winter, P. S., Shalek, A. K., et al. (2025). Adapting systems biology to address the complexity of human disease in the single-cell era. Na-ture Reviews Genetics, 26(8), 514–531.DOI: https://doi.org/10.1038/s41576-025-00821-6
Gunasekaran, B., Arifin, A. H., Wong, W. H. Y., et al. (2025). Precision medicine in neurodegen-erative diseases: From research to clinical practice. Progress in Brain Research, 297, 1–52. DOI: https://doi.org/10.1016/bs.pbr.2025.08.006
Jasieniecka, A., & Domingues, I. (2025). CRISPR-Cas9 and its bio-informatics tools: A systematic review. Current Issues in Molecular Biology, 47(5), 307. DOI: https://doi.org/10.3390/cimb47050307
Lazoka, S. (2025). Incurable dis-eases: Challenges and progress. Multidisciplinary Journal of Science and Technology, 5(6), 2055–2057. https://www.mjstjournal.com/index.php/mjst/article/view/4336
Lin, Y., Yoo, J. M., Vendruscolo, M., & Lee, Y.-H. (2025). Dis-ease–disease interactions: Molec-ular links of neurodegenerative diseases with cancer, viral infec-tions, and type 2 diabetes. Trans-lational Neurodegeneration, 14, 52. DOI: https://doi.org/10.1186/s40035-025-00507-3
Menon, A. V., Song, B., Chao, L., et al. (2025). Unraveling the future of genomics: CRISPR, single-cell omics, and applications in cancer and immunology. Frontiers in Ge-nome Editing, 7, Article 1565387. DOI: https://doi.org/10.3389/fgeed.2025.1565387
Park, S.-J., Lee, G. E., Cho, S. M., & Choi, E.-H. (2025). Recent ap-plications, future perspectives, and limitations of the CRISPR-Cas system. Molecular Therapy – Nu-cleic Acids, 28, 102634. DOI: https://doi.org/10.1016/j.omtn.2025.102634
Sharma, A. (2025). Recent ad-vancements in the therapeutic approaches for Alzheimer’s disease. MedChemDaily, 2025. DOI: https://doi.org/10.1039/d4md00630e
Weiner, H. L. (2025). Immune mechanisms and shared immune targets in neurodegenerative dis-eases. Nature Reviews Neurology, 21(1), 67–85. DOI: https://doi.org/10.1038/s41582-024-01046-7
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.